The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Szalóki, Gábor ^a   Krasznai, Zoárd T ^a   Tóth, Agnes ^a   Vzkeleti, Laura ^a   Szöllosi, Attila G ^a   Trencsényi, György ^a   Lajtos, Imre ^a   Juhász, István ^a   Krasznai, Zoltán ^a   Márián, Teréz ^a   Balázs, Margit ^a   Szabó, Gábor ^a   Goda, Katalin ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; MESSENGER RNA; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; UIC2 MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLOSPORIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SIZE; CELL KILLING; CELL VIABILITY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; EC50; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KB 3 1 CELL LINE; KB V1 CELL LINE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; POSITRON EMISSION TOMOGRAPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SCID MOUSE; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL CARCINOMA CELL LINE; XENOTRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IMMUNOLOGY; MULTIDRUG RESISTANCE; PHYSIOLOGY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CYCLOSPORINE; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; HUMANS; MICE, SCID; P-GLYCOPROTEIN;

EID: 84907195350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107875     Document Type: Article

References (42)

1. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58.
2. Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71: 537-592.
3. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1: 27-42.
4. Rosenberg MF, Callaghan R, Ford RC, Higgins CF (1997) Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis. J Biol Chem 272: 10685-10694.
5. Senior AE (2012) Two ATPases. J Biol Chem 287: 30049-30062.
6. Ambudkar SV, Kim IW, Sauna ZE (2006) The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur J Pharm Sci 27: 392-400.
7. Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8: 411-424.
8. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, et al. (1994) Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502.
9. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, et al. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drugtransporting) P-glycoproteins. Proc Natl Acad Sci U S A 94: 4028-4033.
10. Friedenberg WR, Rue M, Blood EA, Dalton WS, Shustik C, et al. (2006) Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group. Cancer 106: 830-838.
11. Chico I, Kang MH, Bergan R, Abraham J, Bakke S, et al. (2001) Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol 19: 832-842.
12. Szakacs G, Varadi A, Ozvegy-Laczka C, Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13: 379-393.
13. Chaudhary PM, Mechetner EB, Roninson IB (1992) Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80: 2735-2739.
14. Mechetner EB, Roninson IB (1992) Efficient inhibition of P-glycoproteinmediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A 89: 5824-5828.
15. Rittmann-Grauer LS, Yong MA, Sanders V, Mackensen DG (1992) Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft. Cancer Res 52: 1810-1816.
16. Jachez B, Cianfriglia M, Loor F (1994) Modulation of human P-glycoprotein epitope expression by temperature and/or resistance-modulating agents. Anticancer Drugs 5: 655-665.
17. Watanabe T, Naito M, Kokubu N, Tsuruo T (1997) Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK-16 antibodies. J Natl Cancer Inst 89: 512-518.
18. Naito M, Watanabe T, Tsuge H, Koyama T, Oh-hara T, et al. (1996) Potentiation of the reversal activity of SDZ PSC833 on multi-drug resistance by an anti-P-glycoprotein monoclonal antibody MRK-16. Int J Cancer 67: 435-440.
19. Schinkel AH, Arceci RJ, Smit JJ, Wagenaar E, Baas F, et al. (1993) Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein. Int J Cancer 55: 478-484.
20. Zhou Y, Gottesman MM, Pastan I (1999) The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2. Arch Biochem Biophys 367: 74-80.
21. Nagy H, Goda K, Fenyvesi F, Bacsó Z, Szilasi M, et al. (2004) Distinct groups of multidrug resistance modulating agents are distinguished by competition of Pglycoprotein- specific antibodies. Biochem Biophys Res Commun 315: 942-949.
22. Goda K, Fenyvesi F, Bacsó Z, Nagy H, Márián T, et al. (2007) Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody. J Pharmacol Exp Ther 320: 81-88.
23. Krasznai ZT, Tóth A, Mikecz P, Fodor Z, Szabó G, et al. (2010) Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDG. Eur J Pharm Sci 41: 665-669.
24. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, et al. (1998) FDG accumulation and tumor biology. Nucl Med Biol 25: 317-322.
25. Wahl RL (1996) Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. J Nucl Med 37: 1038-1041.
26. Mankoff DA, Bellon JR (2001) Positron-emission tomographic imaging of cancer: glucose metabolism and beyond. Semin Radiat Oncol 11: 16-27.
27. Shen DW, Cardarelli C, Hwang J, Cornwell M, Richert N, et al. (1986) Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261: 7762-7770.
28. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11: 117-126.
29. Hamacher K, Coenen HH, Stocklin G (1986) Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27: 235-238.
30. Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, et al. (2007) Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 6: 2065-2072.
31. Márián T, Szabó G, Goda K, Nagy H, Szincsák N, et al. (2003) In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance. Eur J Nucl Med Mol Imaging 30: 1147-1154.
32. Bosma MJ, Carroll AM (1991) The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 9: 323-350.
33. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6: 343-357.
34. Yano S, Hanibuchi M, Nishioka Y, Nokihara H, Nishimura N, et al. (1999) Combined therapy with anti-P-glycoprotein antibody and macrophage colonystimulating factor gene transduction for multiorgan metastases of multidrugresistant human small cell lung cancer in NK cell-depleted SCID mice. Int J Cancer 82: 105-111.
35. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PH, et al. (2010) Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 184: 512-520.
36. van de Winkel JG, Anderson CL (1991) Biology of human immunoglobulin G Fc receptors. Journal of leukocyte biology 49: 511-524.
37. Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19: 275-290.
38. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, Gerritsen AF, Pluyter M, et al. (2004) Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 173: 4699-4707.
39. Sikic BI, Fisher GA, Lum BL, Halsey J, Beketic-Oreskovic L, et al. (1997) Modulation and prevention of multidrug resistance by inhibitors of Pglycoprotein. Cancer Chemother Pharmacol 40 Suppl: S13-19.
40. Loscher W, Potschka H (2005) Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2: 86-98.
41. Bougoin S, Lomet D, Kerboeuf D, Le Vern Y, Malpaux B, et al. (2008) Evidence that the choroids plexus in female sheep express P-glycoprotein. Neuro Endocrinol Lett 29: 438-442.
42. Gottesman MM, Ludwig J, Xia D, Szakacs G (2006) Defeating drug resistance in cancer. Discov Med 6: 18-23.